Aquestive Therapeutics presented at the H.C. Wainwright 27th Annual Global Investment Conference providing insights into their product candidates and commercialization strategies.
Advancement of Anaphylm (dibutepinephrine) Sublingual Film
Aquestive highlighted the advancement and regulatory approval process of Anaphylm, the oral administration of epinephrine.
Adrenaverse Pipeline Growth
The company discussed the growth and clinical development plans for their Adrenaverse pipeline epinephrine prodrug product candidates, including AQST-108 (epinephrine) Topical Gel.
Commercial Opportunities
Insights were shared regarding the commercial opportunities and potential market growth for products like Libervant® (diazepam) Buccal Film, Anaphylm, and AQST-108, if approved.
- Aquestive Therapeutics emphasized the importance of their product candidates in addressing medical needs and potential market expansions.
- The company outlined risks and uncertainties associated with their development work and regulatory approval processes.
Overall, Aquestive Therapeutics showcased a strong commitment to innovation and addressing medical challenges through their product pipeline and commercialization strategies.